Endocrine pharmacologyCharacteristics of Repaglinide (cas 108157-52-4) effects on insulin secretion

Add time:08/23/2019    Source:sciencedirect.com

The dynamics of insulin secretion stimulated by Repaglinide (cas 108157-52-4), a glinide, and the combinatorial effects of repaglinide and incretin were investigated. At 4.4 mM glucose, repaglinide induced insulin secretion with a gradually increasing first phase, showing different dynamics from that induced by glimepiride, a sulfonylurea. In the presence of glucagon-like peptide-1 (GLP-1), insulin secretion by repaglinide was augmented significantly but to lesser extent and showed different dynamics from that by glimepiride. At 4.4 mM glucose, the intracellular Ca2+ level was gradually increased by repaglinide alone or repaglinide plus GLP-1, which differs from the Ca2+ dynamics by glimepiride alone or glimepiride plus GLP-1, suggesting that the difference in Ca2+ dynamics contributes to the difference in the dynamics of insulin secretion. At a higher concentration (8.8 mM) of glucose, the dynamics of insulin secretion stimulated by repaglinide was similar to that by glimepiride. Combination of repaglinide and GLP-1 significantly augmented insulin secretion, the amount of which was comparable to that by the combination of glimepiride and GLP-1. The Ca2+ dynamics was similar for repaglinide and glimepiride at 8.8 mM glucose. Our data indicate that repaglinide has characteristic properties in its effects on the dynamics of insulin secretion and intracellular Ca2+ and that the combination of repaglinide and GLP-1 stimulates insulin secretion more effectively than the combination of glimepiride and GLP-1 at a high concentration of glucose, providing a basis for its use in clinical settings.

We also recommend Trading Suppliers and Manufacturers of Repaglinide (cas 108157-52-4). Pls Click Website Link as below: cas 108157-52-4 suppliers

Prev:ArticleThe Structural Basis for the Binding of Repaglinide (cas 108157-52-4) to the Pancreatic KATP Channel
Next:Identification of Repaglinide (cas 108157-52-4) as a therapeutic drug for glioblastoma multiforme)